Table 1.
Clinical characteristics | Pre EGFR-TKI N (%) |
Post EGFR-TKI N (%) |
Paired samples N (%) |
||
---|---|---|---|---|---|
Total | 200 | 136 | 38 | ||
Median (range) | 63 (23–89) | 61 (29–86) | 62 (34–84) | ||
Female | 134 (67) | 41 (30) | 27 (71) | ||
Former smoker | 82 (41) | 57 (42) | 16 (42) | ||
Median pack-yr (range) | 6 (1–125) | 0 (0–110) | 0 (0–30) | ||
Large cell neuroendocrine | 0 (0) | 1 (0.7) | 0 (0) | 0 (0) | |
EGFR mutation | |||||
EGFR T790M | 0 (0) | 70 (52) | 0 (0) | 16 (42) | |
Exon 19 deletion | 90 (45) | 78 (57) | 17 (45) | ||
L858R | 72 (36) | 43 (32) | 15 (39) | ||
Exon 20 insertions | 7 (3.5) | 1 (0.7) | 0 (0) | ||
Exon 18 deletion | 5 (2.5) | 4 (3) | 3 (8) | ||
Exon 19 insertion | 3 (1.5) | 1 (0.7) | 1 (3) | ||
L861Q | 6 (3) | 2 (1.5) | 0 (0) | ||
G719A | 3 (1.5) | 2 (1.5) | 0 (0) | ||
L747P | 3 (1.5) | 0 (0) | 0 (0) | ||
E709X+G719X | 4 (2) | 0 (0) | 0 (0) | ||
G719X+S768I | 2 (1) | 3 (2) | 0 (0) | ||
G719X+L861Q | 3 (1.5) | 0 (0) | 0 (0) | ||
EGFR-KDD | 2 (1) | 2 (1.5) | 2 (5) | ||
Prior treatment | |||||
Erlotinib | 0 (0) | 128 (94) | 0 (0) | 36 (95) | |
Afatinib | 0 (0) | 6 (4) | 0 (0) | 2 (5) | |
Dacomitinib | 0 (0) | 2 (1) | 0 (0) | 0 (0) |